HRP20220762T1 - Upotreba pilokarpin-hidroklorida u liječenju prezbiopije - Google Patents
Upotreba pilokarpin-hidroklorida u liječenju prezbiopije Download PDFInfo
- Publication number
- HRP20220762T1 HRP20220762T1 HRP20220762TT HRP20220762T HRP20220762T1 HR P20220762 T1 HRP20220762 T1 HR P20220762T1 HR P20220762T T HRP20220762T T HR P20220762TT HR P20220762 T HRP20220762 T HR P20220762T HR P20220762 T1 HRP20220762 T1 HR P20220762T1
- Authority
- HR
- Croatia
- Prior art keywords
- vol
- preparation
- pilocarpine hydrochloride
- accordance
- vision
- Prior art date
Links
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 title claims 9
- 229960002139 pilocarpine hydrochloride Drugs 0.000 title claims 9
- 201000010041 presbyopia Diseases 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 claims 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 230000004438 eyesight Effects 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 5
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 4
- 239000004327 boric acid Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 3
- 208000001491 myopia Diseases 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000000149 argon plasma sintering Methods 0.000 claims 1
- 229960002645 boric acid Drugs 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229960000443 hydrochloric acid Drugs 0.000 claims 1
- 230000004297 night vision Effects 0.000 claims 1
- 229960002668 sodium chloride Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662144P | 2018-04-24 | 2018-04-24 | |
| US201862780117P | 2018-12-14 | 2018-12-14 | |
| US201962790957P | 2019-01-10 | 2019-01-10 | |
| PCT/US2019/028917 WO2019209955A2 (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
| EP19729883.9A EP3681500B2 (en) | 2018-04-24 | 2019-04-24 | Use of pilocarpine hydrochloride for the treatment of presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220762T1 true HRP20220762T1 (hr) | 2022-09-16 |
Family
ID=66821312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220762TT HRP20220762T1 (hr) | 2018-04-24 | 2019-04-24 | Upotreba pilokarpin-hidroklorida u liječenju prezbiopije |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10610518B2 (enExample) |
| EP (2) | EP4066830A1 (enExample) |
| JP (3) | JP6946575B2 (enExample) |
| KR (2) | KR20210005134A (enExample) |
| CN (1) | CN112272558A (enExample) |
| AU (3) | AU2019261598B9 (enExample) |
| BR (1) | BR112020021845A2 (enExample) |
| CA (2) | CA3162141A1 (enExample) |
| CL (1) | CL2020002734A1 (enExample) |
| CO (1) | CO2020014563A2 (enExample) |
| CY (1) | CY1125325T1 (enExample) |
| DK (1) | DK3681500T3 (enExample) |
| ES (1) | ES2920803T5 (enExample) |
| HR (1) | HRP20220762T1 (enExample) |
| HU (1) | HUE058931T2 (enExample) |
| IL (1) | IL278178A (enExample) |
| LT (1) | LT3681500T (enExample) |
| MX (1) | MX2020011301A (enExample) |
| PH (1) | PH12020551766A1 (enExample) |
| PL (1) | PL3681500T3 (enExample) |
| PT (1) | PT3681500T (enExample) |
| RS (1) | RS63360B1 (enExample) |
| SG (1) | SG11202010472XA (enExample) |
| SI (1) | SI3681500T1 (enExample) |
| WO (1) | WO2019209955A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102654048B1 (ko) | 2017-07-20 | 2024-04-03 | 세인다 파마슈티컬 광저우 코포레이션 | 근시 치료용 조성물 및 방법 |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| CN113164451A (zh) | 2018-10-15 | 2021-07-23 | 奥库菲尔制药股份有限公司 | 治疗青光眼的方法和组合物及相关病症 |
| EP3870170A4 (en) | 2018-10-26 | 2022-07-20 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES |
| AU2021338618B2 (en) * | 2020-09-11 | 2024-02-01 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
| JP2024505517A (ja) * | 2021-01-28 | 2024-02-06 | グラウコス コーポレイション | 製剤 |
| WO2022232205A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | A method of reducing brow ache |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| EP4433053A4 (en) | 2021-11-17 | 2025-09-17 | Lenz Therapeutics Operations Inc | ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE |
| CN116350790B (zh) | 2021-12-28 | 2025-02-07 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
| US20230270671A1 (en) * | 2022-01-14 | 2023-08-31 | Somerset Therapeutics, Llc | Pharmaceutically stable pilocarpine formulations with substantially reduced buffer content and related methods |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
| CN119584954A (zh) | 2022-04-21 | 2025-03-07 | 格劳科斯公司 | 眼用局部乳膏组合物 |
| CN119546278A (zh) | 2022-05-18 | 2025-02-28 | 格劳科斯公司 | 两性离子在眼用局部乳膏组合物和制剂中的新应用 |
| CN117243888A (zh) * | 2023-09-22 | 2023-12-19 | 南京海纳制药有限公司 | 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| US5055467A (en) | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
| US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
| US5776916A (en) | 1990-07-10 | 1998-07-07 | Gramer; Eugen | Medicament for reducing the intraocular pressure |
| JP2536806B2 (ja) | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| WO1994001096A1 (en) | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| SE512871C2 (sv) | 1992-08-20 | 2000-05-29 | Santen Oy | Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension |
| AU5599594A (en) * | 1992-11-16 | 1994-06-08 | Ciba-Geigy Ag | Polyvinyl alcohol/borate ophthalmic drug delivery system |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| US5574518A (en) | 1995-01-10 | 1996-11-12 | Les Laboratoires Opti-Centre Inc. | System incorporation two different sphero-non-spherical contact lenses for correcting presbytia |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6164282A (en) | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
| CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
| IT1306135B1 (it) * | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
| US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
| EP1214065A4 (en) | 1999-09-16 | 2009-01-07 | Ocularis Pharma Inc | METHOD USING THE ALPHA AGONIST TO OPTIMIZE THE SIZE OF THE PUPIL |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| AU2001291159A1 (en) | 2000-09-20 | 2002-04-02 | Shahinian Jr., Lee | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| ITMI20010708A1 (it) | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
| US20030139737A1 (en) | 2002-01-24 | 2003-07-24 | J.T. Lin | Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift |
| ES2397574T3 (es) | 2002-07-30 | 2013-03-08 | Omeros Corporation | Procedimiento y soluciones de irrigación oftalmológica |
| US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
| US20070211212A1 (en) | 2002-09-26 | 2007-09-13 | Percy Bennwik | Eye state sensor |
| US20040078009A1 (en) | 2002-10-17 | 2004-04-22 | Lin J. T. | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means |
| US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
| US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| NZ540885A (en) | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| JP4308255B2 (ja) | 2004-05-21 | 2009-08-05 | 千寿製薬株式会社 | ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤 |
| US20050279369A1 (en) | 2004-06-21 | 2005-12-22 | Lin J T | Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation |
| JP2008517671A (ja) | 2004-10-22 | 2008-05-29 | アキュフォーカス・インコーポレーテッド | 光学装置を目の軸に位置合わせするためのシステム及び方法 |
| BRPI0615432A2 (pt) | 2005-09-02 | 2011-05-17 | Theravida Inc | composição farmacêutica, e, uso de compostos |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CA2658394C (en) | 2006-07-12 | 2016-08-16 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| EP1938839B1 (en) | 2006-12-18 | 2009-08-19 | Jorge Luis Benozzi | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| BRPI0819081A8 (pt) | 2007-10-08 | 2016-08-30 | Fovea Pharmaceuticals Sa | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| AU2015202175A1 (en) | 2007-12-15 | 2015-05-14 | Anant Sharma | Optical correction |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| TW201109325A (en) | 2009-07-30 | 2011-03-16 | Wakamoto Pharma Co Ltd | Aqueous composition for eye drops |
| AR081049A1 (es) | 2010-08-17 | 2012-06-06 | Gonzalez Santos Alejandro Raul | Medicamento oftalmico para el tratamiento de la hipermetropia |
| US9119772B2 (en) * | 2011-01-26 | 2015-09-01 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
| BR112014006607A2 (pt) | 2011-09-20 | 2017-04-25 | Allergan Inc | composições e métodos para tratamento de presbiopia, hiperopia leve e astigmatismo irregular |
| KR20140103099A (ko) | 2011-10-12 | 2014-08-25 | 아센디스 파마 옵탈몰로지 디비젼 에이/에스 | 안구 병태의 예방 및 치료 |
| RU2014129268A (ru) | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля |
| EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| EP2950800B1 (en) | 2013-02-01 | 2020-09-09 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| CA2899339C (en) | 2013-02-01 | 2021-07-06 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US8859623B1 (en) | 2013-11-14 | 2014-10-14 | Paragon BioTeck, Inc. | Methods and compositions of stable phenylephrine formulations |
| ES2538551B1 (es) | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| ES2834334T3 (es) | 2014-01-10 | 2021-06-17 | Santen Pharmaceutical Co Ltd | Preparación farmacéutica que incluye compuesto de ácido piridilaminoacético |
| CN106456584A (zh) | 2014-02-11 | 2017-02-22 | 阿拉西斯医药公司 | 用于矫正老视的药理学眼科用组合物和其施用 |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20190000808A1 (en) | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CH711969A2 (it) | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| US10231968B2 (en) | 2016-08-01 | 2019-03-19 | David R. Hardten | Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies |
| CN116726006A (zh) | 2016-08-19 | 2023-09-12 | 阿拉西斯医药公司 | 眼科药物组合物及其相关用途 |
| EP4241759A1 (en) | 2016-10-12 | 2023-09-13 | PS Therapy, Inc. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
-
2019
- 2019-04-24 KR KR1020207033656A patent/KR20210005134A/ko not_active Ceased
- 2019-04-24 HR HRP20220762TT patent/HRP20220762T1/hr unknown
- 2019-04-24 RS RS20220575A patent/RS63360B1/sr unknown
- 2019-04-24 SG SG11202010472XA patent/SG11202010472XA/en unknown
- 2019-04-24 ES ES19729883T patent/ES2920803T5/es active Active
- 2019-04-24 CA CA3162141A patent/CA3162141A1/en active Pending
- 2019-04-24 CN CN201980037652.3A patent/CN112272558A/zh active Pending
- 2019-04-24 MX MX2020011301A patent/MX2020011301A/es unknown
- 2019-04-24 PL PL19729883.9T patent/PL3681500T3/pl unknown
- 2019-04-24 AU AU2019261598A patent/AU2019261598B9/en not_active Ceased
- 2019-04-24 LT LTEPPCT/US2019/028917T patent/LT3681500T/lt unknown
- 2019-04-24 WO PCT/US2019/028917 patent/WO2019209955A2/en not_active Ceased
- 2019-04-24 EP EP22160205.5A patent/EP4066830A1/en active Pending
- 2019-04-24 SI SI201930260T patent/SI3681500T1/sl unknown
- 2019-04-24 JP JP2020559558A patent/JP6946575B2/ja active Active
- 2019-04-24 CA CA3074618A patent/CA3074618C/en active Active
- 2019-04-24 KR KR1020237017632A patent/KR20230079489A/ko active Pending
- 2019-04-24 PT PT197298839T patent/PT3681500T/pt unknown
- 2019-04-24 US US16/393,175 patent/US10610518B2/en active Active
- 2019-04-24 HU HUE19729883A patent/HUE058931T2/hu unknown
- 2019-04-24 DK DK19729883.9T patent/DK3681500T3/da active
- 2019-04-24 BR BR112020021845-6A patent/BR112020021845A2/pt not_active IP Right Cessation
- 2019-04-24 EP EP19729883.9A patent/EP3681500B2/en active Active
-
2020
- 2020-02-14 US US16/791,039 patent/US11285134B2/en active Active
- 2020-05-21 AU AU2020203311A patent/AU2020203311A1/en not_active Abandoned
- 2020-10-20 IL IL278178A patent/IL278178A/en unknown
- 2020-10-22 CL CL2020002734A patent/CL2020002734A1/es unknown
- 2020-10-23 PH PH12020551766A patent/PH12020551766A1/en unknown
- 2020-11-24 CO CONC2020/0014563A patent/CO2020014563A2/es unknown
-
2021
- 2021-09-15 JP JP2021150116A patent/JP7470667B2/ja active Active
-
2022
- 2022-01-12 US US17/647,813 patent/US20220241245A1/en not_active Abandoned
- 2022-02-18 AU AU2022201106A patent/AU2022201106A1/en not_active Abandoned
- 2022-06-22 CY CY20221100430T patent/CY1125325T1/el unknown
-
2024
- 2024-03-29 US US18/621,624 patent/US20240382462A1/en not_active Abandoned
- 2024-04-08 JP JP2024062082A patent/JP2024096131A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220762T1 (hr) | Upotreba pilokarpin-hidroklorida u liječenju prezbiopije | |
| JP2022008403A5 (enExample) | ||
| HRP20220972T1 (hr) | Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu | |
| WO2016172712A3 (en) | Ophthalmic composition | |
| ES2460570T3 (es) | Composiciones oftálmicas que contienen una combinación sinérgica de tres polímeros | |
| WO2018033792A3 (en) | Ophthalmic pharmaceutical compositions and uses relating thereto | |
| WO2008011836A3 (es) | Soluciones oftálmicas | |
| CL2013002467A1 (es) | Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular. | |
| MX2012000889A (es) | Compuesto biciclico y uso del mismo para propositos medicos. | |
| MX2010007295A (es) | Composiciones acuosas estables de ciclosporina. | |
| BR112015001158A2 (pt) | formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia | |
| FI2034956T4 (fi) | Matalan viskositeetin omaavia glykosaminoglykaaneja käsittäviä koostumuksia ja mainitun koostumuksen käyttö kroonisen kystiitin terapiassa | |
| WO2008089268A3 (en) | Methods and compositions for treating conditions associated with infection and/or inflammation | |
| MX364260B (es) | Uso de lentes de contacto en el tratamiento de una afección oftalmológica. | |
| EP3650012A4 (en) | SOLID COMPOSITION CONSISTING OF AN AGENT OF IODINE AND SODIUM CHLORIDE HAVING AN IMPROVED SOLUBILITY IN WATER, AND ANTIVIRAL AND ANTIMICROBIAL COMPOSITION FOR IL, ORAL CAVITY, NASAL CAVITY OR INHALATION CONTAINING AN AQUEOUS SOLUTION OF THE SAME- THIS | |
| FI3846810T3 (fi) | Lasmiditaanin pitkäkestoinen yöaikainen annostus migreenin ennaltaehkäisyyn | |
| CL2016000160A1 (es) | Pelicula oral que comprende hidroxipropilcelulosa sola o combinada con polivinilpirrolidona, al menos un copolímero de vinilpirrolidona, dioxido de titanio, en donde la relación del copolímero de vinilpirrolidona con el dioxido de titanio es de 3 es a 1 a 5 es a 1, y rizatriptán, zolmitriptán, alprazolam, diazepam o lorazepam, como principio activo. | |
| JP2014506927A5 (enExample) | ||
| ATE358474T1 (de) | Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung | |
| MY204185A (en) | Composition and methods for the treatment of myopia | |
| WO2019195761A3 (en) | Pharmacological agents for treating ocular diseases | |
| RU2014140885A (ru) | Фармацевтическая композиция ибупрофена и трамадола для офтальмологического применения | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| JP2018532806A5 (enExample) | ||
| KR102582048B1 (ko) | 점안제 |